Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol.
The proliferation and differentiation of normal prostate epithelial cells depends upon the action of androgens produced by the testis. Prostate cancers retain the ability to respond to androgens in the initial stages of cancer development, but progressively become independent of exogenous androgens in advanced stages of the disease while maintaining the expression of functional androgen receptor (AR). In the present study, we have determined the potential of prostate cancer cells to synthesize androgens from cholesterol which may be involved in intracrine regulation of AR in advanced stages of the disease. Established androgen-independent prostate cancer cell lines, PC3 and DU145 cells, expressed mRNA and proteins for scavenger receptor type B1 (SRB1), steroidogenic acute regulatory (StAR) protein, cytochrome P450 cholesterol side chain cleavage (P450scc), 3beta-hydroxysteroid dehydrogenase (3beta-HSD) and other enzymes involved in androgen biosynthesis. Expression of all these proteins and enzymes was significantly higher in the androgen-independent derivative of LNCaP prostate cancer cells (C81) than in the androgen-dependent cell line (C33). In serum-free cultures, the androgen-independent C81 cells secreted approximately 5-fold higher testosterone than C33 cells as determined in the conditioned media by immunoassays. These cells could also directly convert radioactive cholesterol into testosterone which was identified by thin layer chromatography. These results for the first time show that prostate cancer cells in advanced stages of the disease could synthesize androgens from cholesterol and hence are not dependent upon testicular and/or adrenal androgens.
Dillard
Paulette R
PR
Department of Biological Sciences, Clark Atlanta University, Atlanta, GA 30314, United States.
Lin
Ming-Fong
MF
Khan
Shafiq A
SA
D000728:Androgens / Q000378:metabolism*; D019898:Autocrine Communication; D045744:Cell Line, Tumor; D002784:Cholesterol / Q000378:metabolism*; D015971:Gene Expression Regulation, Enzymologic; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000201:enzymology / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D012333:RNA, Messenger / Q000378:metabolism; D013739:Testosterone / Q000378:metabolism*; D015854:Up-Regulation
D000728:Androgens; D012333:RNA, Messenger; D013739:Testosterone; D002784:Cholesterol
Prostate. 2007 Apr 1;67(5):557-71
17221842
Prostate. 2003 Mar 1;54(4):249-57
12539223
Oncogene. 2007 Mar 8;26(11):1606-15
16964290
Eur Urol. 1997;32 Suppl 3:24-40
9267783
Nat Med. 2004 Jan;10(1):33-9
14702632
Endocr Relat Cancer. 2005 Mar;12(1):101-7
15788642
J Clin Endocrinol Metab. 1972 Jan;34(1):177-84
5061771
Oncogene. 2006 Jun 22;25(26):3719-34
16449965
JAMA. 2005 Sep 14;294(10):1255-9
16160134
Clin Cancer Res. 2005 Jul 1;11(13):4653-7
16000557
Cancer Res. 2006 Mar 1;66(5):2815-25
16510604
J Clin Oncol. 2002 Jul 1;20(13):3001-15
12089231
Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8462-7
9237999
Cancer Res. 2004 Oct 1;64(19):7156-68
15466214
Cancer Res. 2003 Sep 1;63(17):5622-8
14500404
Endocrinology. 1999 Mar;140(3):1481-91
10067877
Cancer Res. 2007 May 15;67(10):5033-41
17510436
Mol Cell Endocrinol. 2004 Sep 30;224(1-2):29-39
15353178
Endocrinology. 1997 Nov;138(11):4876-82
9348218
Minerva Endocrinol. 2006 Mar;31(1):1-12
16498360
Clin Cancer Res. 2004 Jan 15;10(2):440-8
14760063
Steroids. 1997 Jan;62(1):148-58
9029730
Arthritis Res Ther. 2005;7(5):R938-48
16207335
Am J Pathol. 2004 Jan;164(1):217-27
14695335
J Clin Endocrinol Metab. 2004 May;89(5):2434-41
15126575
Annu Rev Physiol. 2001;63:193-213
11181954
Prostate. 2002 Mar 1;50(4):222-35
11870800
Surg Gynecol Obstet. 1969 Jan;128(1):117
5774991
Nat Rev Cancer. 2001 Oct;1(1):34-45
11900250